MAGFORCE USA FIGHTING CANCER WITH NANOTHERM THERAPY SPARED CRN Meeting May 3, 2018 MagForce AG Company Presentation Berlin, Germany
2 AGENDA • NANOTHERM THERAPY • ABLATION OF PROSTATE LESIONS Company Presentation MagForce AG Berlin, Germany O:\Word\2018\SPARED\SPARED CRN 050318
3 WHO WE ARE • Larry Kessler, Sc.D. • Professor, University of Washington, School of Public Health • David Hammond, MS • Hammond Clinical Trial Consulting, LLC • Affiliate faculty, University of Washington, School of Pharmacy Company Presentation MagForce AG Berlin, Germany O:\Word\2018\SPARED\SPARED CRN 050318
4 NANOTHERM ABLATION TUMOR ABLATION FROM THE INSIDE OUT : Therapy components NanoPlan NanoTherm NanoActivator Brain (EU approved) Pancreas (Phase II) Prostate (Phase I) 12nm Core Coating Functional surface (Aminosilane) Mode of action Step 2 Step 1 Step 3 • NanoTherm magnetic fluid injected • The simulation takes into account the • Magnetic field causes NanoTherm directly into tumor tissue tumor size, distribution of the particles to oscillate and produce heat NanoTherm particles and tumor • Nanoparticles remain in place due to • Heat destroys or makes cells location their special coating susceptible to concomitant radio- or • Simulated temperature distribution: chemotherapy 40 ° C (blue line) to 50 ° C (red line) Company Presentation MagForce AG Berlin, Germany O:\Word\2018\SPARED\SPARED CRN 050318
5 NANOTHERM THERAPY – STRATEGY DEVELOPMENT & EXECUTION Focus on application of NanoTherm therapy for the treatment of • Brain tumors (Germany & EU 27) and • Intermediate risk prostate cancer (USA) PREVIOUS EUROPEAN CLINICAL TREATMENT EXPERIENCE MagForce AG has CE Indication Patients mark in Germany and Glioblastoma Multiforme 80 in the EU27 to treat brain cancers with Prostate Cancer 29 NanoTherm therapy Esophageal Cancer 10 Pancreatic Cancer 7 Other Indications ~20 Company Presentation MagForce AG Berlin, Germany O:\Word\2018\SPARED\SPARED CRN 050318
6 ABLATION OF PROSTATE LESIONS MagForce AG Company Presentation Berlin, Germany
7 NANOTHERM THERAPY FOR THE ABLATION OF INTERMEDIATE RISK PROSTATE CANCER LESIONS – MAGFORCE USA, INC. Average distance from NanoTherm Ablation 50 ° C iso-contour line to the simulated 43 ° C iso-contour line A Distance measurements A-D B D between the 50 ° C ( red ) ablation contour line and the 43 ° C ( green ) no damage C contour line (H = 10 kA/m). Company Presentation MagForce AG Berlin, Germany O:\Word\2018\SPARED\SPARED CRN 050318
8 MGF-0115 CLINICAL STUDY – A PIVOTAL, PROSPECTIVE, THREE-STAGE, SINGLE-ARM STUDY OF FOCAL ABLATION OF THE PROSTATE WITH NANOTHERM THERAPY SYSTEM FOR LIMITED-VOLUME, CLINICALLY LOCALIZED, INTERMEDIATE-RISK PROSTATE CANCER Study Stage Description: Stage I: 10 patient study Will demonstrate adequate ablation of tumor tissue Will demonstrate lack of ablation outside target zone Ablative NanoActivation Time: 60 minutes Company Presentation MagForce AG Berlin, Germany O:\Word\2018\SPARED\SPARED CRN 050318
Nutrition and Cancer: Fighting Cancer With Food Fighting Cancer With Food
Antiproton Cancer Therapy AD- -4/ACE 4/ACE Antiproton Cancer Therapy AD
Duration of Adjuvant Therapy for Colon Cancer Anthony F. Shields, M.D., Ph.D.
TAILORED ADJUVANT SYSTEMIC THERAPY FOR BREAST CANCER THERAPY FOR BREAST
Chimeric Antigen Receptor (CAR) T Cell Therapy: A Cure for Cancer? Michael
New Zealands GMO releases: Oncolytic viruses for cancer therapy clinical
2012 HKUST iGEM Team B. hercules The Terminator of Colon Cancer Background
Tailoring Cancer Therapy in the Molecular Age Nancy E. Davidson, M.D.
Modern Radiation Therapy Opportunities for Improved Cancer Control Mary
RADIOFREQUENCY ABLATION ELIZABETH DAVID MD FRCPC VASCULAR AND INTERVENTIONAL
Visualase Therapy: A New & Exciting Technology Jessica Anne Wilden MD
What Are My Treatment Options for AF? Mikhael El-Chami, MD FACC, FHRS Emory
Practical Approaches to Atrial Fibrillation Management Answ ers to Your
Venous Reflux Duplex Exam GWENDOLYN CARMEL, RVT PHYSIOLOGIST, DEPARTMENT OF
Ablation vs. Amiodarone for Treatment of Atrial Fibrillation in Patients with
Progress in Fielding a Zero- Focus Shadowgraph System for Ablation
Adjuvant Therapy of Thyroid Cancer: rhTSH, RAI, EBRT and Targeted Therapeutics
L ABLATION DANS LES ABLATION DANS LES L ARYTHMIES ARYTHMIES
Beth Israel Deaconess Medical Center Radiology Presentation Schedule Sunday,
Laser Rework Capabilities Utilizing different laser wavelengths allow for
Investor Presentation 4Q 2018 Stereotaxis at a Glance Global Leader in